Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state

Area of Science:

• Genomics and Bioinformatics
• Cancer Research
• Drug Discovery and Development

Background:

• Omics technologies are crucial for precision medicine but require integration into drug discovery workflows.
• Developing novel anticancer agents necessitates understanding drug mechanisms and predicting therapeutic response.

Purpose of the Study:

• To demonstrate the utility of multi-omics data integration in advancing the development of novel anticancer agents.
• To establish a versatile platform for combining RNA-seq and Assay for Transposase-Accessible Chromatin (ATAC-seq) data.
• To guide the development of 3-chloropiperidines as a new class of anticancer therapeutics.

Main Methods:

• Integrated analysis of transcriptome (RNA-seq) and chromatin accessibility (ATAC-seq) data.
• Development of a novel strategy for versatile omics data integration.
• Construction of a perturbation-informed basal signature to predict cancer cell line sensitivity.

Main Results:

• Elucidation of mechanisms underlying sensitivity to candidate anticancer agents.
• Demonstration that the integrated omics platform accelerates and enhances standalone analyses.
• Identification of a predictive signature for guiding compound development against specific tumor types.

Conclusions:

• The developed multi-omics pipeline offers a scalable approach for early-stage drug discovery.
• This strategy enhances the understanding of drug mechanisms and aids in positioning therapeutics.
• The approach supports precision medicine by enabling targeted drug development for specific cancers.